Endobronchial Ultrasound Biopsy Market

Endobronchial Ultrasound Biopsy Market Forecast and Outlook By FMI

In 2025, the endobronchial ultrasound biopsy market was valued at USD 0.77 billion. Based on Future Market Insights’ analysis, demand for endobronchial ultrasound biopsy systems and dedicated consumables is estimated to grow to USD 0.82 billion in 2026 and USD 1.52 billion by 2036. FMI projects a CAGR of 6.3% during the forecast period.

Absolute dollar growth of about USD 0.69 billion over the decade signals steady expansion driven by guideline-backed lung cancer staging volumes and broader bronchoscopy programme build-outs, rather than a single product-cycle spike. Growth stays measured because capital budgets for scopes and processors compete with CT, MRI, and surgical backlogs, while procedure throughput depends on sedation capacity and trained bronchoscopists.

Summary of the Endobronchial Ultrasound Biopsy Market

• Market definition
  • Endobronchial ultrasound biopsy demand is driven by hospital and clinic purchasing of EBUS scopes, ultrasound imaging platforms, and dedicated biopsy consumables used for minimally invasive lung cancer staging and mediastinal sampling.
• Demand drivers
  • Lung cancer diagnostic pathways increasingly specify minimally invasive mediastinal staging steps, lifting procedure volumes where bronchoscopy suites have trained staff and ultrasound platforms. [2]
  • Specimen processing and handling standards are becoming more formalised, supporting repeatable diagnostic yield and reducing avoidable re-biopsies. [3]
  • Product development aimed at workflow efficiency, including scope design changes that cut pre-procedure setup steps, supports broader centre adoption. [5]
• Key segments analysed
  • Product outlook: EBUS Scopes lead demand, estimated at 33% share in 2026 due to their gatekeeper role in EBUS procedures and replacement cycles in high-volume centres.
  • Procedure outlook: Convex-probe (Linear / CP-EBUS) Scopes hold 61.1% share in 2026 because they enable real-time needle guidance for mediastinal staging.
  • Geography: Asia Pacific drives incremental volume growth as tertiary hospitals expand interventional pulmonology capacity and training pipelines.
• Analyst opinion at FMI
  • Sabyasachi Ghosh, Senior Consultant at Future Market Insights, opines, “Buyers will see that the winning strategy is pairing scope and processor upgrades with specimen workflow discipline, because diagnostic yield and turnaround time now shape procurement decisions as much as capital cost.”
• Strategic implications
  • Build bundled offerings that link scopes, processors, and consumables with service uptime commitments and clinical training to reduce site-to-site variability in outcomes.
  • Prioritise compatibility and workflow integration across bronchoscopy suites, pathology, and oncology teams to protect sample adequacy for biomarker testing.
  • Focus commercial expansion on large hospital networks and teaching centres where procedure volumes justify capex and where training capacity is scalable.
• Methodology
  • Forecasts triangulate guideline direction with installed base replacement cycles and procedure pathway adoption.
  • Country outlook integrates system-specific constraints such as reimbursement rules, public pathway mandates, and procurement centralisation.
  • Evidence is validated through primary interviews and cross-checking against public guideline and manufacturer disclosures. [2] [3] [5]

As Luann Marie Pendy, Senior Corporate Managing Officer at Olympus, noted regarding care pathway priorities, “We will focus on enhancing patient care pathways where Olympus can elevate the standard of care.” [1]

China (8.5% CAGR) and India (7.9% CAGR) lead growth as tertiary hospitals widen minimally invasive mediastinal staging and clinician training pathways. Germany (7.2%) and France (6.6%) benefit from structured oncology care, multidisciplinary tumour boards, and guideline-aligned staging protocols. The United Kingdom (6.0%) grows through standardised pathways and staged diagnostic timelines in the NHS. The United States (5.4%) sustains demand via high screening-driven workups and mature reimbursement structures, with growth paced by device replacement cycles and cost scrutiny. Brazil (4.7%) expands from a smaller base, with uptake concentrated in urban referral centres and constrained by uneven reimbursement.

Market Definition

The endobronchial ultrasound biopsy market covers devices and consumables used to visualise airways and lymph nodes with ultrasound from inside the bronchial tree and to collect tissue samples for diagnosis and staging. It includes EBUS bronchoscopes, ultrasound processors and imaging systems, and biopsy tools such as EBUS-TBNA needles that enable sampling of mediastinal and hilar lymph nodes. Demand is tied to lung cancer staging, evaluation of suspicious lymphadenopathy, and pulmonary lesion workups where minimally invasive approaches reduce surgical biopsies.

Market inclusions

This report covers global and regional market sizing for 2026 to 2036, with a 2025 base year anchor and segment forecasts by product outlook, procedure outlook, end-use outlook, and region. It includes demand drivers tied to lung cancer pathways, bronchoscopy suite capacity, and specimen handling practices, along with competitive assessment of leading device manufacturers and consumable suppliers operating across major healthcare systems.

Market exclusions

The scope excludes broader bronchoscopy categories that are not EBUS-guided, such as routine flexible diagnostic bronchoscopy without ultrasound guidance, and it excludes surgical mediastinoscopy equipment. It also omits downstream oncology therapeutics, imaging modalities such as CT and PET systems, and laboratory-only molecular diagnostics platforms unless directly linked to biopsy sampling requirements and workflow constraints.

Endobronchial Ultrasound Biopsy Market Research methodology

• Primary research: Primary interviews were conducted with interventional pulmonologists, bronchoscopy suite managers, hospital procurement leads, and medical device distributors focused on respiratory endoscopy and ultrasound platforms.
• Desk research: Desk research drew from published clinical guidelines, pathway documents, professional society updates on specimen handling, and manufacturer disclosures on respiratory endoscopy product portfolios and launches. [2] [3] [4]
• Market-sizing and forecasting: Market sizing follows a hybrid approach, combining bottom-up procedure volume logic (staging and diagnostic use cases) with top-down validation against device installed base dynamics across hospitals, ASCs, and specialty clinics.
• Data validation and update cycle: Forecast outputs are cross-checked against guideline updates, public pathway changes, and product cycle milestones. Assumptions are refreshed on a defined update cadence using triangulation across clinician inputs and published sources.

Segmental analysis

Endobronchial ultrasound biopsy Market Analysis by Product outlook

Based on FMI’s endobronchial ultrasound biopsy market report, consumption of EBUS Scopes is estimated to hold 33% share in 2026. This segment leads because EBUS scopes are the enabling asset for ultrasound-guided staging and biopsy, and they anchor the recurring pull-through of needles, sheaths, and processing accessories as procedure volumes rise in high-throughput bronchoscopy suites.

• Portfolio expansion: Fujifilm announced a new flexible ultrasound bronchoscope designed to simplify pre-procedure preparation through a balloonless structure, targeting workflow efficiency for pulmonology teams. [5]
• Platform integration: Manufacturers continue to position EBUS scopes as part of integrated respiratory endoscopy stacks, tying scope upgrades to imaging improvements and care pathway performance metrics. [1]
• Consumables pull-through: As specimen handling and yield expectations rise, centres tend to standardise dedicated EBUS-TBNA needles and biopsy consumables to reduce re-biopsy risk and protect diagnostic timelines. [3]

Endobronchial ultrasound biopsy Market Analysis by Procedure outlook

Based on FMI’s endobronchial ultrasound biopsy market report, consumption of Convex-probe (Linear / CP-EBUS) Scopes is estimated to hold 61.1% share in 2026. CP-EBUS dominates because it supports real-time needle guidance for mediastinal and hilar lymph node sampling, aligning with staging pathways where nodal confirmation influences treatment selection and radiotherapy planning.

• Clinical pathway fit: NICE lung cancer guidance keeps diagnosis and staging steps tightly linked to confirmed sampling in relevant scenarios, supporting CP-EBUS use in staging workflows. [2]
• Specimen quality focus: CHEST issued guidance on handling EBUS-TBNA specimens, reinforcing the operational link between CP-EBUS procedure steps and downstream pathology readiness. [3]
• Staging accuracy evidence: Peer-reviewed findings continue to compare systematic endoscopic staging approaches against imaging-only planning, supporting continued preference for endosonography-led staging pathways in appropriate cases. [8]

Endobronchial ultrasound biopsy Market Drivers, Restraints, Opportunities

Future Market Insights analysis links market size to lung cancer workups where mediastinal staging, nodal assessment, and sampling quality directly influence treatment selection. In health systems with defined staging pathways, EBUS is positioned as a minimally invasive option that can reduce surgical sampling, shorten diagnostic timelines, and support multidisciplinary decision-making when bronchoscopy suites have trained operators and reliable imaging platforms. [2]

Procurement tension sits between the value of faster, safer staging and the cost structure of capex plus recurring consumables. Centres without stable sedation capacity, pathology turnaround, or trained bronchoscopists can struggle to justify new EBUS platforms. At the same time, specimen handling standards and workflow tools are pushing hospitals to treat EBUS as part of an end-to-end pathway rather than a standalone scope purchase, which changes vendor selection criteria from unit price to service, training, and integration. [3]

• Specimen workflow standards: Professional society guidance on processing and handling EBUS-TBNA specimens raises expectations for repeatability and sample adequacy, supporting investment in standardised kits and training. [3]
• Guideline-driven staging demand: National and regional lung cancer guidance reinforces invasive mediastinal staging steps in defined clinical scenarios, supporting steady procedure volumes. [2]
• Asia Pacific capacity build: China and India are expanding tertiary care infrastructure and interventional pulmonology training capacity, which lifts the installed base and procedure throughput for EBUS programmes. [6] [7]

Regional Analysis

The endobronchial ultrasound biopsy market is tracked across North America, Europe, Asia Pacific, Latin America, and Middle East and Africa, reflecting differences in lung cancer pathways, bronchoscopy suite capacity, reimbursement models, and clinician training infrastructure. The full report includes market attractiveness analysis by country and segment.

Source: Future Market Insights (FMI) analysis, based on proprietary forecasting model and primary research

North America market analysis

North America is a pathway-and-reimbursement anchored market, where procedure volumes are supported by organised oncology pathways, coding clarity, and hospital network standardisation. Major players such as Olympus and Fujifilm compete on imaging performance, service uptime, and training support for interventional pulmonology programmes, while accessory and consumable suppliers compete on sampling reliability and specimen adequacy aligned to biomarker testing needs. [3] [5]

• United States: Demand for endobronchial ultrasound biopsy in the United States is projected to rise at 5.4% CAGR through 2036. Adoption is reinforced by the operational need to stage disease accurately before therapy selection, which pushes providers to maintain EBUS capacity in tertiary centres and large networks. In October 2024, CHEST released guidance on processing and handling EBUS-TBNA specimens, signalling that specimen workflow discipline is part of clinical quality, not a back-office detail. [3] In parallel, guideline-driven staging pathways remain active, with UK and European guidance often used as operational references in multinational clinical programmes and academic centres, reinforcing the role of ultrasound-guided staging and sampling in structured lung cancer workups. [2] In the device layer, manufacturers continue to launch and refresh respiratory endoscopy platforms that position bronchoscopy as a high-throughput diagnostic service line, which supports steady replacement and upgrade cycles in major hospitals. [1]

FMI’s analysis of endobronchial ultrasound biopsy market in North America consists of country-wise assessment that includes the United States. Readers can find procedure-led demand modelling, installed base replacement logic, and hospital versus outpatient site-of-care shifts.

Europe market analysis

Europe functions as a guideline-dense market where multidisciplinary tumour boards and structured care pathways shape how staging and sampling are sequenced. Vendors compete on compliance documentation, service coverage, and clinical evidence support, while hospitals often standardise platforms across networks to simplify training and maintenance. [2]

• Germany: Demand for endobronchial ultrasound biopsy in Germany is projected to rise at 7.2% CAGR through 2036. Germany’s oncology guideline ecosystem supports consistent staging practice, which sustains baseline EBUS volumes across thoracic centres. The German S3 lung cancer guideline programme has issued updated long-version documents that reflect living-guideline updates and revisions to diagnostic sections and molecular workup considerations, reinforcing the operational need for reliable sampling pathways that protect downstream treatment decisions. [9] Hospitals also rely on structured clinical governance, which tends to favour vendors that can document performance, service uptime, and staff training. On the evidence side, peer-reviewed discussions of mediastinal staging continue to reinforce the role of endosonography-led approaches as part of modern staging algorithms, supporting ongoing procedural demand in advanced centres. [8]
• France: Demand for endobronchial ultrasound biopsy in France is projected to rise at 6.6% CAGR through 2036. French clinical practice is shaped by structured thoracic oncology coordination and pathway discipline, which supports minimally invasive staging and sampling when it shortens time-to-treatment. In February 2024, OncoBFC published an updated NSCLC reference document that sets expectations for qualified centres and structured decision-making, reinforcing the role of organised diagnostic and staging pathways in authorised settings. [10] France also draws on broader European guidance and evidence streams that emphasise accurate mediastinal staging as a decision point for therapy strategy, sustaining the rationale for EBUS investment in high-volume sites. [8]
• United Kingdom: Demand for endobronchial ultrasound biopsy in the United Kingdom is projected to rise at 6.0% CAGR through 2036. UK demand is tied to pathway timing, capacity planning, and standardisation across NHS services rather than only device availability. NICE’s lung cancer guideline NG122 was updated in March 2024, keeping diagnosis and staging guidance current and reinforcing structured staging decisions in the pathway. [2] The National Optimal Lung Cancer Pathway (versioned for January 2024) frames operational expectations around reducing variation and delays, which supports hospitals investing in bronchoscopy and EBUS capacity to meet pathway performance targets. [4]

FMI’s analysis of endobronchial ultrasound biopsy market in Europe consists of country-wise assessment that includes Germany, France, and the United Kingdom. Readers can find pathway timing impacts, procurement centralisation effects, and segment demand splits by procedure type and end-use.

Asia Pacific market analysis

Asia Pacific is the capacity expansion region, with demand shaped by tertiary hospital build-outs, clinician training pipelines, and rising lung cancer screening and workup volumes in major urban centres. Global manufacturers compete alongside regional suppliers through distributor networks, education programmes, and bundled offerings that lower barriers to adoption for new bronchoscopy suites. [5]

• China: Demand for endobronchial ultrasound biopsy in China is projected to rise at 8.5% CAGR through 2036. Growth is tied to expanding diagnostic capacity in tertiary hospitals and structured efforts to strengthen lung cancer screening and early detection. In 2024, Chinese medical association guidance for lung cancer screening was updated, reflecting ongoing refinement of risk models and screening approaches for high-risk groups, which can increase downstream diagnostic workups that require staging and sampling capacity. [6] On the clinical utilisation side, China continues to produce large-cohort evidence on EBUS-TBNA use and performance in real-world settings, reinforcing the technique’s role in minimally invasive diagnosis and staging pathways and supporting wider centre adoption as training spreads. [7]
• India: Demand for endobronchial ultrasound biopsy in India is projected to rise at 7.9% CAGR through 2036. Uptake is led by metro tertiary hospitals and teaching centres where interventional pulmonology has expanded as a service line tied to oncology. In 2024, Lung India published clinical work examining EBUS-TBNA performance in mediastinal staging, reflecting the ongoing institutionalisation of EBUS within staging protocols and training contexts. [11] India also shows formal procurement signals for bronchoscopy and EBUS infrastructure in public institutions, including tender documentation for bronchoscopy and EBUS-related training or simulation requirements, which indicates systematic capacity building rather than isolated purchases. [12]

FMI’s analysis of endobronchial ultrasound biopsy market in Asia Pacific consists of country-wise assessment that includes China and India. Readers can find hospital versus clinic adoption patterns, training capacity effects, and vendor go-to-market levers tied to workflow and service coverage.

Latin America market analysis

Latin America is an urban-centre led adoption region where procedure volumes concentrate in large referral hospitals and private networks. Suppliers often win through training support, distributor reach, and service availability, with reimbursement variability shaping how widely EBUS programmes move beyond major cities.

• Brazil: Demand for endobronchial ultrasound biopsy in Brazil is projected to rise at 4.7% CAGR through 2036. Growth is supported by expanding attention to lung cancer screening and structured recommendations that increase downstream staging and biopsy demand in appropriate patients. In 2024, Brazilian lung cancer screening recommendations were published in the peer-reviewed literature, reflecting a system move toward more organised screening logic that can increase diagnostic throughput and require reliable staging pathways. [13] Brazil also contributes region-specific evidence and discussion around EBUS-TBNA’s role in mediastinal staging, supporting clinical adoption and reinforcing how sampling quality influences treatment planning. [14]

FMI’s analysis of endobronchial ultrasound biopsy market in Latin America consists of country-wise assessment that includes Brazil. Readers can find adoption constraints by site of care, payer coverage impacts, and consumables demand tied to procedure volumes.

Competitive Aligners for Market Players

Competition is moderately concentrated in platforms and more fragmented in accessories and consumables. Large imaging and endoscopy companies anchor the installed base through scope and processor ecosystems, while biopsy needle and accessory providers compete on sampling reliability, ease of use, and compatibility across common bronchoscope families. Workflow integration and service coverage are primary competitive variables because bronchoscopy suites value uptime, predictable maintenance, and consistent performance under high procedure loads.

Structural advantage sits with players that control both scopes and imaging platforms, because they can bundle upgrades, training, and service contracts into network-level procurement. Platform suppliers also influence standardisation decisions across hospital systems, which can lock in downstream consumables and accessories through compatibility requirements and clinician familiarity. Guidance on specimen handling increases the value of training and standard operating procedures, making vendor education programmes and accessory standardisation part of the commercial playbook. [3]

Buyer leverage varies by site of care. Large hospital networks and teaching systems often negotiate multi-year contracts that include service-level commitments, loaner programmes, and training credits, reducing the supplier’s pricing power on capital equipment. Smaller hospitals and specialty clinics are more sensitive to capex and may prioritise workflow simplification and lower maintenance burden, which favours products that reduce setup steps and support predictable throughput. [5]

Recent Developments

• June 2024: American College of Chest Physicians (CHEST) announced a new guideline on collection, processing, and handling of EBUS-TBNA specimens, shaping clinical workflow expectations for biopsy programmes. [3]
• March 2024: NICE updated NG122 "Lung cancer: diagnosis and management", keeping UK staging and diagnostic pathway guidance current for service planning and procurement. [2]
• January 2024: The National Optimal Lung Cancer Pathway documentation framed best-practice pathway steps to reduce delays and variation, reinforcing operational pressure for timely staging capacity in NHS services. [4]

Key Players in the Endobronchial Ultrasound Biopsy Market

• Olympus Corporation
• GE HealthCare
• Siemens Healthineers AG
• Koninklijke Philips N.V.
• Boston Scientific Corporation
• Cook Group Incorporated
• FUJIFILM Holdings Corporation
• Medi-Globe Technologies GmbH
• ACE Medical Devices Pvt. Ltd.
• Praxis Medical

Scope of the Report

Endobronchial Ultrasound Biopsy Market Analysis by Segments

By Product outlook:

• EBUS Scopes
• EBUS-TBNA Needles & Dedicated Biopsy Consumables
• Ultrasound Processors and Imaging Systems
• Accessories & Ancillaries (sheaths, forceps, adapters, sterilization consumables)

By Procedure outlook:

• Convex-probe (Linear / CP-EBUS) Scopes
• Radial-probe (RP-EBUS) Scopes

By End-use outlook:

• Hospitals (Community Hospitals, Academic/Teaching Hospitals, Large MultispecialtyHospitals/Networks)
• Ambulatory Surgical Centers (Independent ASCs, Hospital-Affiliated ASCs)
• Specialty Clinics

By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Bibliography

• [1] Olympus Corporation. (2023, November). Integrated report 2023 (English).
• [2] National Institute for Health and Care Excellence. (2024, March). Lung cancer: Diagnosis and management (NG122): Diagnosis and staging (Last updated March 8, 2024).
• [3] American College of Chest Physicians. (2024, October). Guideline on handling endobronchial ultrasound transbronchial needle samples [Press release].
• [4] NHS RM Partners. (2024, January 1). National optimal lung cancer pathway (Version 4).
• [5] FUJIFILM. (2026, January). FUJIFILM’s new flexible ultrasound bronchoscope for lung cancer detection and staging (EB-710US).
• [6] Chinese Medical Association. (2024). Chinese Medical Association guideline for clinical lung cancer screening (2024).
• [7] Liao, H., et al. (2024). Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) real-world cohort study.
• [8] Steinfort, D. P., et al. (2024). Systematic endoscopic staging of mediastinum to guide radiotherapy planning.
• [9] Leitlinienprogramm Onkologie (AWMF). (2025, April). Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms (Langversion 4.0).
• [10] OncoBFC, & Oncologik. (2024, February 7). Cancer bronchique non à petites cellules (Version publiée).
• [11] Shah, E., et al. (2024, March). Accuracy of endobronchial ultrasound (EBUS) in mediastinal lung cancer staging. Lung India.
• [12] National Investigation Agency (India). (2021). Tender: GI endoscopy ERCP, EUS, bronchoscope, EBUS simulator.
• [13] Pereira, L. F. F., et al. (2024). Lung cancer screening in Brazil: Recommendations.
• [14] Braga, S., et al. (2024). EBUS-TBNA in mediastinal staging of non-small cell lung cancer. Jornal Brasileiro de Pneumologia.

This Report Addresses

• Market sizing for 2025 base year with forecasts from 2026 to 2036 for the global endobronchial ultrasound biopsy market
• Segment forecasts by product outlook, procedure outlook, and end-use outlook with share tracking for leading sub-segments
• Country-wise growth outlook and demand modelling across priority markets with pathway and reimbursement context
• Competitive assessment of platform suppliers and consumables players, including go-to-market and service coverage factors
• Tracking of clinical guideline and workflow standard changes that affect biopsy yield, specimen handling, and procurement criteria
• Identification of high-opportunity settings by site of care, including hospital networks, teaching centres, and outpatient expansion scenarios
• Deliverables provided in analyst report format with supporting tables and narrative insights for procurement and strategy teams